To Compare the Efficacy and Safety of Low-dose Glucocorticoids and Tofacitinib in Alleviating Moderate to High Disease Activity Rheumatoid Arthritis for 24 Weeks
Rheumatoid Arthritis
About this trial
This is an interventional treatment trial for Rheumatoid Arthritis focused on measuring rheumatoid arthritis, moderate disease activity, high disease activity
Eligibility Criteria
Inclusion Criteria: Age 18-70 years; met the 2010 ACR and EULAR diagnostic criteria for rheumatoid arthritis (RA), and was diagnosed as RA; After more than 3 months of initial treatment or conventional DMARDs treatment, the disease was still in medium-high disease activity, and DAS28-CRP>3.2; No birth plan during and within 3 months after the end of the study; Voluntarily sign the informed consent form. Exclusion Criteria: Patients who are using or have used glucocorticoids, tofacitib and biological agents in the past 3 months; At the time of screening, patients were in the acute phase of acute infection or chronic infection; Laboratory test results: Hb<100g/L; White blood cell count <4.0×10^9/L; Platelets <100×10^9/L; Liver function (transaminase, bilirubin)> 2 times the upper limit of normal value; Renal function (SCr) > the upper limit of normal; Active gastrointestinal disease: gastrointestinal bleeding or active gastrointestinal ulcer and acute gastric mucosal injury diagnosed by gastroenteroscopy in the past three months; A history of severe cardiovascular, cerebrovascular, kidney and other important organs, blood and endocrine system lesions, malignant tumors and thrombosis; suffering from serious, progressive and uncontrolled diseases of other important organs and systems; mental disease patients; Other conditions deemed unsuitable for trial participation by the investigator; Pregnancy tests of women of childbearing age were positive.
Sites / Locations
- Changxing Country People's HospitalRecruiting
- Jiaxing Central Hospital
- Jinhua Central HospitalRecruiting
- Shaoxing Central HospitalRecruiting
- Zhuji People's HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
Glucocorticoid group
Tofacitinib group